10-K · August 19, 2026
INBS delivered strong top-line momentum, with fiscal 2026 revenue up 38.1% to $4.22 million and gross margin improving to 48.6%, driven overwhelmingly by the United Kingdom. However, operating losses widened to $12.61…
Earnings analysis · 10-K
INBS earnings analysis
Filed October 21, 2026 · Our reading of the company's report
The latest report
This Form 10-K/A is narrowly focused on executive compensation, related-party transactions, and exhibit corrections; it does not update the company’s financial statements or provide guidance. The amended disclosures…
Read full summary
This Form 10-K/A is narrowly focused on executive compensation, related-party transactions, and exhibit corrections; it does not update the company’s financial statements or provide guidance. The amended disclosures show a product roadmap tied to clinical, FDA, and commercial milestones, but also highlight significant reliance on equity financing and a sizable warrant overhang. The absence of updated operating and liquidity data, together with continued potential dilution, leaves the investment outlook high risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Roadmap tied to FDA and commercial milestones
The company’s 2026 executive performance objectives included “financial liquidity targets,” FDA submissions, and operational goals related to IFP. Performance-based restricted stock awards allocate 40% of vesting to completion of a specified FDA regulatory submission.
-
Equity incentives aligned with product execution
On March 18, 2026, the company granted each of the CEO and CFO 21,350 performance-vesting shares, with vesting also linked to specified clinical-trial and commercial supply and sales milestones.
-
Raised approximately $5.0 million
Alyeska participated in the December Private Placement for total gross proceeds of approximately $5.0 million, providing financing support for the company’s operations.
-
Board independence maintained
The board determined that each director was independent under Nasdaq Rule 5605(a)(2), and independent directors constituted a majority of the full board.
What to watch
-
Large warrant overhang and dilution
The December Private Placement included 1,044,425 Series L pre-funded warrants, 1,149,425 Series K-1 warrants, and 1,149,425 Series K-2 warrants issued to Alyeska. During fiscal 2026, Alyeska also exercised warrants for 216,247 common shares for aggregate proceeds of $118,109, creating substantial potential dilution.
-
Continued equity issuance may dilute holders
The 2019 Long Term Incentive Plan covers 179,500 shares, with only 3,265 shares remaining available for future issuance as of June 30, 2026. The company also granted 5,000 restricted shares to each non-employee director on March 18, 2026.
-
No updated financial or liquidity disclosure
This amendment states that it “does not contain or amend any disclosure with respect to Items 307 and 308” and that no financial statements are included. Consequently, the amendment provides no updated revenue, earnings, cash-flow, liquidity, or operating-trend information beyond the original filing.
-
Related-party financing concentration
The amendment newly discloses that Alyeska, a beneficial owner of more than 5% of common stock, participated in multiple financing transactions, including approximately $831,368 of gross proceeds in the 2025 Warrant Inducement Transaction and approximately $5.0 million in the December Private Placement.
Management's outlook
This Form 10-K/A contains no financial statements or quantitative outlook; it amends Items 11, 13, and 15 of the original 10-K only. Annual outlook is not provided in this amendment.
Earlier filings 2
10-Q · May 13, 2026
Intelligent Bio Solutions Inc. reported positive revenue growth of 46% year-over-year in Q3 2026, reaching $1,060,802, driven by an increase in customer acquisitions. Despite higher operating expenses leading to a net…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.